Lipid-free structure and stability of apolipoprotein A-I: probing the central region by mutation.
To probe the structure and stability of the central region of lipid-free apolipoprotein (apo) A-I (residues 123-165), we studied the effects of four mutations made in this region on the conformation, stability, dimyristoylphosphatidylcholine (DMPC) binding kinetics, and size of discoidal reconstituted high-density lipoprotein (rHDL) particles. The apoA-I deletion delta(144-165) leads to a red shift in the wavelength of maximum fluorescence and a reduction in the alpha-helical content, the stability, the initial rate of association with DMPC liposomes, and the size of the discoidal particles. The data are consistent with the helical structure of residues 144-165, and the deletion appears to perturb the tertiary organization of the N-terminal half of apoA-I. In contrast, the deletion of the adjacent region, delta(136-143), leads to stabilization without altering the number of residues in the helical conformation or the initial rate of association with DMPC liposomes. The quadruple substitution E125K/E128K/K133E/E139K leads to approximately 17 additional residues in the helical conformation and an increase in the stability, the initial rate of association with DMPC liposomes, and the size of the rHDL particles. The findings are consistent with the disordered structure of the segment of residues 123-142, which becomes helical as a result of the quadruple mutation or upon lipid binding. The naturally occurring mutation L141R (also associated with coronary heart disease) that is located in this segment does not change the protein conformation but leads to a reduced stability and a decreased rate of association with DMPC liposomes that may relate to the observed altered functions of this mutant.
Gorshkova
Irina N
IN
Department of Physiology and Biophysics and Section of Molecular Genetics, Whitaker Cardiovascular Institute, Boston University School of Medicine, 715 Albany Street, Boston, Massachusetts 02118, USA.
Liu
Tong
T
Zannis
Vassilis I
VI
Atkinson
David
D
D019943:Amino Acid Substitution / Q000235:genetics; D016632:Apolipoprotein A-I / Q000737:chemistry* / Q000235:genetics* / Q000302:isolation & purification / Q000648:ultrastructure; D008076:Cholesterol, HDL / Q000235:genetics / Q000378:metabolism; D004134:Dimyristoylphosphatidylcholine / Q000737:chemistry; D019791:Guanidine / Q000737:chemistry; D006358:Hot Temperature; D006801:Humans; D007700:Kinetics; D008055:Lipids / Q000737:chemistry / Q000235:genetics*; D008081:Liposomes / Q000737:chemistry; D016297:Mutagenesis, Site-Directed; D010316:Particle Size; D010446:Peptide Fragments / Q000737:chemistry / Q000235:genetics* / Q000648:ultrastructure; D010713:Phosphatidylcholines / Q000737:chemistry / Q000235:genetics; D011485:Protein Binding / Q000235:genetics; D011489:Protein Denaturation / Q000235:genetics; D017510:Protein Folding; D017433:Protein Structure, Secondary; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000737:chemistry / Q000302:isolation & purification / Q000648:ultrastructure; D017384:Sequence Deletion; D013050:Spectrometry, Fluorescence
D016632:Apolipoprotein A-I; D008076:Cholesterol, HDL; D008055:Lipids; D008081:Liposomes; D010446:Peptide Fragments; D010713:Phosphatidylcholines; D011994:Recombinant Proteins; D019791:Guanidine; C028694:1-palmitoyl-2-oleoylphosphatidylcholine; D004134:Dimyristoylphosphatidylcholine